Global Arthritis Pain Injection Drug Market Growth (Status and Outlook) 2023-2029

Global Arthritis Pain Injection Drug Market Growth (Status and Outlook) 2023-2029

The global Arthritis Pain Injection Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Arthritis Pain Injection Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Arthritis Pain Injection Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Arthritis Pain Injection Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Arthritis Pain Injection Drug players cover Bioventus Inc., Pacira BioSciences, Inc., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc., Anika Therapeutics, Inc., Zimmer Biomet Holdings, Inc., Eli Lilly And Company and Ferring Holdings SA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

LPI (LP Information)' newest research report, the “Arthritis Pain Injection Drug Industry Forecast” looks at past sales and reviews total world Arthritis Pain Injection Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Arthritis Pain Injection Drug sales for 2023 through 2029. With Arthritis Pain Injection Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Arthritis Pain Injection Drug industry.

This Insight Report provides a comprehensive analysis of the global Arthritis Pain Injection Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Arthritis Pain Injection Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Arthritis Pain Injection Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Arthritis Pain Injection Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Arthritis Pain Injection Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Arthritis Pain Injection Drug market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Steroid Injections Drug
Hyaluronic acid Injections Drug
Others

Segmentation by application
Knee and Ankle
Shoulder and Elbow
Hip Joint
Facet Joints of the Spine
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bioventus Inc.
Pacira BioSciences, Inc.
AbbVie, Inc.
Teva Pharmaceuticals Industries Ltd.
Pfizer, Inc.
Anika Therapeutics, Inc.
Zimmer Biomet Holdings, Inc.
Eli Lilly And Company
Ferring Holdings SA
Sanofi S.A.

Please note: The report will take approximately 2 business days to prepare and deliver.